Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. (6th September 2014)

• Record Type: Journal Article
• Authors: van der Velden, Walter J. F. M.; Herbers, Alexandra H. E.; Netea, Mihai G.; Blijlevens, Nicole M. A.
• Is Part Of: British journal of haematology. Volume 167:Number 4(2014:Nov.)
• Page Start: 441
• Page End: 452
• Publication Date: 2014-09-06
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.13113
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh13113-abs-0001"> <title>Summary</title> <p>Infection remains one of the most prominent complications after cytotoxic treatment for cancer. The connection between neutropenia and both infections and fever has long been designated as 'febrile neutropenia', but treatment with antimicrobial agents and haematopoietic growth factors has failed to significantly reduce its incidence. Moreover, emerging antimicrobial resistance is becoming a concern that necessitates the judicious use of available antimicrobial agents. In addition to neutropenia, patients who receive cytotoxic therapy experience mucosal barrier injury (MBI) or 'mucositis'. MBI creates a port‐de‐entrée for resident micro‐organisms to cause blood stream infections and contributes directly to the occurrence of fever by disrupting the highly regulated host‐microbe interactions, which, even in the absence of an infection, can result in strong inflammatory reactions. Indeed, MBI has been shown to be a pivotal factor in the occurrence of inflammatory complications after cytotoxic therapy. Hence, the concept 'febrile neutropenia' alone may no longer suffice and a new concept 'febrile mucositis' should be recognized as the two are at least complementary. This review we summarizes the existing evidence for both paradigms and proposes new therapeutic approaches to tackle the perturbed host‐microbe interactions arising from cytotoxic therapy‐induced tissue damage in order to reduce fever in neutropenic patients with cancer.</p> </abstract>